TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01323309

Intervention type: BEHAVIORAL
Intervention: Individual Meaning-Centered Psychotherapy (IMCP)
Description: IMCP is based on the principles of Viktor Frankl's Logotherapy, and is designed to help patients with advanced cancer sustain or enhance a sense of meaning, peace and purpose in their lives even as they approach the end of life. IMCP is structured as a 7-session (1-hour weekly sessions) individual intervention that utilizes a mixture of didactics, discussion and experiential exercises that focus around particular themes related to meaning and advanced cancer. In addition we will be asking patients in the IMCP arm to complete an optional weekly session rating survey

Intervention type: BEHAVIORAL
Intervention: standard Individual Supportive Psychotherapy (ISP)
Description: The ISP intervention utilized as the comparison treatment condition in this study, is adapted from the Supportive Group Psychotherapy manualized intervention developed by David Payne (1997) and adapted by Drs. Kissane, Breitbart and colleagues into the ISP manualized intervention. This intervention is a 7-session individual supportive psychotherapy utilizing an approach to supportive psychotherapy based on models described by Rogers. The essential components of supportive psychotherapy are integrated into this manualized intervention, including: reassurance, explanation, guidance, suggestion, encouragement, affecting changes in patient's environment, and permission for catharsis.

Intervention type: BEHAVIORAL
Intervention: enhanced usual care (EUC)
Description: We are therefore including what we refer to as an enhanced usual care arm to this randomized controlled trial to address the ethical issues raised by utilizing a usual care condition in a vulnerable advanced cancer population. Participants will receive feedback about their level of distress (based on the DT administered at screening) and given appropriate targeted referrals based on levels of distress and problem areas endorsed. Participants will be given a letter with a list of appropriate referrals.
Study: NCT00228020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF, cyclosporine, steroids
Study: NCT02552004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pCLE
Description: Histological examination by pCLE technique preceding the frozen section

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV fluorescein administration
Description: IV Fluorescein (fluorescent contrast agent) administration
Study: NCT01898819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study: NCT02467790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX168
Description: PEX 168: 200µg,Subcutaneous,one time.
Study: NCT01898819

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Study: NCT00818857

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early Intervention
Description: At the point of randomization the early group will receive increasingly intensive reminders to complete specific cancer screening tests.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed intervention
Description: One year from the point of randomization patients will begin to receive increasingly intensive reminders to complete specific cancer screening tests.
Study: NCT02771951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lights of Change

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Study: NCT03137303

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spirometry at initial visit
Description: Initial visit for the intervention group, an initial demographics form and health questionnaires. To evaluate the breathing, a pre and post broncho dilator will be performed as well as a spirometry test.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol
Description: The post broncho dilator spirometry test will be preformed after a breathing medication called Albuterol. Albuterol is used in standard practice for COPD and is commonly used during spirometry.
Study: NCT02815904

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional handling
Description: Positioning of preterm infants for optimal physiological development

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesthetic stimulation
Description: For kinesthetic stimulation, all the limbs were given six passive flexion and extension movements
Study: NCT03137303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: The post broncho dilator spirometry test will be preformed after a breathing medication called Albuterol. Albuterol is used in standard practice for COPD and is commonly used during spirometry.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Spirometry at 12-month follow-up
Description: At the end of the 1 year followup, the patient will be scheduled for a pre and post BD spirometry test and undergo the same spirometry protocol as the intervention group.
Study: NCT02561858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acid load test
Study: NCT02170987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate high

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03604081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIMT
Description: Intervention group will receive one hour of intense massed practice of lower extremity either in the form of shaping or task practice.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Physical Therapy
Description: 1 hour as per current standard of care that follows stroke clinical practice guideline.
Study: NCT00717990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 2000 mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 7.5 mg/kg intravenous (IV) on day 1 every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 250 mg/m2 IV on day 1 every 3 weeks for 6 cycles
Study: NCT01341418

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suprapatellar approach
Description: Suprapatellar surgical approach will be used for intramedullary nailing of tibial fractures. Arthroscopic photos will be obtained before and after nail insertion. Postoperative radiographs, outcome questionnaires and an MRI will be performed over ther course of one-year follow-up.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infrapatellar approach
Description: The Infrapatellar surgical approach will be used for intramedullary nailing of tibial fractures. No arthroscopic examination for this intervention. Postoperative radiographs, outcome questionnaires and an MRI will be performed over ther course of one-year follow-up.
Study: NCT01860222

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SR

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PLAT
Study: NCT02794558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate MRgFUS
Description: MR images of the breast will be obtained for lesion localization purposes. The breast surgeon or the radiologist will make a treatment plan or map. Sonication at therapeutic power level will be performed on multiple overlapping points successively until sonication of the target volume has been completed.~Follow-up evaluation will be made within 14 to 21 days after the MRgFUS treatment.
Study: NCT03244202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid Plus Counselling
Description: The Genomics ADViSER is an decision aid designed to inform patients about genomic sequencing (GS) and aid them selecting which incidental findings they would like to receive from GS.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Genetic Counselling Only
Description: Participants will learn about genomic sequencing and incidental findings by speaking directly with a genetic counsellor and select which incidental findings they would like to receive with a genetic counsellor.
Study: NCT00752999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib Disodium (R935788)
Description: 150 mg tablet, oral, twice-a-day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, oral, twice-a-day
Study: NCT01425541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estrace
Description: 0.5-1 mg once a day PO for 7 days
Study: NCT02852135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA Proseal
Description: After preoxygenation, anaesthesia was induced with propofol, fentanyl and cisatracurium,LMA Proseal was inserted and cuff inflated in each group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA Supreme
Description: After preoxygenation, anaesthesia was induced with propofol, fentanyl and cisatracurium ，LMA Supreme was inserted and cuff inflated in each group.
Study: NCT00734162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Description: TDF administered as a 300-mg tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TDF placebo tablet once daily
Study: NCT01624740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Rate Stimulation
Description: Stimulation was given at a rate of 2 Hz.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Rate Stimulation
Description: Stimulation was given at a rate of 2 Hz.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Rate Stimulation
Description: Stimulation was given at a rate of 1200 Hz.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Rate Stimulation
Description: Stimulation was given at a rate of 1200 Hz.
Study: NCT02815904

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kangaroo Mother Care
Description: Providing skin to skin human touch
Study: NCT01753037

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dehydroepiandrosterone (DHEA)
Description: DHEA 130 mg administered orally for 5 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contained in a capsule that is identical in appearance to the one used to package DHEA for 5 days.
Study: NCT03551730

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRT064445/Enoxaparin

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRT064445/Enoxaparin

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRT064445/Enoxaparin

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo/Enoxaparin

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo/Enoxaparin

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo/Enoxaparin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04207086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib is an oral potent multiple RTK inhibitor that selectively inhibits VEGF receptors, VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), fibroblast growth factor receptor (FGFR1-4), platelet derived growth factor (PDGFRα), stem cell factor receptor (KIT), and rearranged during transfection (RET).
Study: NCT01765556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Description: multiple doses of ketoconazole in Period B and C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: single dose of vemurafenib in Period A and C
Study: NCT03179683

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diode laser application
Description: an 630-660 nm aluminum gallium indium phosphide (AlGalnP) laser device (Scorpion Dental Optima Model 405-7A; Optica Laser, Sofia, Bulgaria) was used immediately after surgery, third day, fifth day and seventh day only for one operation side. Treatment side were randomly selected by another surgeon who applied LLLT. Tissue was irradiated at 25mW power for total six minutes, two minutes for each point (buccal, palatal, crestal). 72J /cm2 energy density was deposited in one session.
Study: NCT03418883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Mirror therapy
Study: NCT01692158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin, Low-Molecular-Weight
Description: single subcutaneuous administration of 40 mg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin, Low-Molecular-Weight
Description: single subcutaneuous administration of 40 mg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.
Study: NCT01016652

Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A multifocal contact lens
Description: low-add multifocal contact lens
Study: NCT02747134

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Regulation and Mindfulness skills

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emotion Regulation and Mindfulness skills
Study: NCT02999555

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovum pickup
Description: Ovum pickup or Egg retrieval, that is performed not for the purpose of the study, but for the purpose of well known in vitro fertilization indications
Study: NCT01924832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: tablet
Study: NCT01425541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: 20 mg/ml, 25-100 mg, Three times a day at 0700, 1500, and 2300 hr for 7 days
Study: NCT05074004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Psychoeducation sessions were conducted by two psychiatric nurses (İK, SS) who are experts in their fields and have psychoeducation and group leadership certificates. Each session was held once a week in 30-45 minutes sessions. The training was carried out interactively; approximately the first 5 minutes were spent on warm-up, the basic information of that day's session was given for 25 minutes, and the last 10 minutes were in the form of questions and answers. Two separate groups were formed according to the day hospital program of the patients, and the psychoeducation program was carried out in two separate groups to conduct psychoeducation effectively.
Study: NCT02739009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR106 single ascending doses, intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo single ascending doses, intravenous
Study: NCT01921439

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Feedback
Description: Personalized feedback reflecting the participant's current level of nicotine addiction, money spent on cigarettes, time spent smoking, and health effects of smoking.
Study: NCT03627481

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery
Description: Endoscopic sinus surgery for nasal polyposis
Study: NCT01140880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Truvada At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Truvada
Description: Truvada At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
Study: NCT02549898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feraheme
Description: Feraheme is an USPIO agent, which will be applied as a contrast agent to visualize vascular inflammation in unilateral migraine without aura.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feraheme
Description: Feraheme is an USPIO agent, which will be applied as a contrast agent to visualize vascular inflammation in unilateral migraine without aura.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feraheme
Description: Feraheme is an USPIO agent, which will be applied as a contrast agent to visualize vascular inflammation in unilateral migraine without aura.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feraheme
Description: Feraheme is an USPIO agent, which will be applied as a contrast agent to visualize vascular inflammation in unilateral migraine without aura.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Cilostazol will be applied to provoke migraine attacks in migraineurs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Cilostazol will be applied to provoke migraine attacks in migraineurs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Cilostazol will be applied to provoke migraine attacks in migraineurs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: USPIO-MRI
Description: USPIO-MRI scans will be performed in order to assess possible vascular inflammation associated with migraine attacks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: USPIO-MRI
Description: USPIO-MRI scans will be performed in order to assess possible vascular inflammation associated with migraine attacks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: USPIO-MRI
Description: USPIO-MRI scans will be performed in order to assess possible vascular inflammation associated with migraine attacks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: USPIO-MRI
Description: USPIO-MRI scans will be performed in order to assess possible vascular inflammation associated with migraine attacks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BBI-MRI
Description: Black blood MRI scans will be performed in order to asses changes in vessel wall thickness due to possible vascular inflammation associated with migraine attacks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BBI-MRI
Description: Black blood MRI scans will be performed in order to asses changes in vessel wall thickness due to possible vascular inflammation associated with migraine attacks.
Study: NCT00910871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207
Description: TMC207 400mg once daily for 2 weeks then 200mg three times a week for 22 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background Regimen (BR) for MDR-TB
Description: Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as specified in the protocol for up to 96 weeks.
Study: NCT01132378

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: staged bilateral total knee arthroplasty (not more than 7 days between surgeries)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: staged bilateral total knee arthroplasty (not more than 7 days between surgeries)
Study: NCT00652496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.01% ophthalmic solution
Description: One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.015% formulation 1 ophthalmic solution
Description: One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.015% formulation 2 ophthalmic solution
Description: One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.02% ophthalmic solution
Description: One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost 0.03% ophthalmic solution
Description: Bimatoprost 0.03% ophthalmic solution, one drop in one eye, once daily in the morning for 4 consecutive days, the other eye received one drop of any of the 4 study drugs
Study: NCT00472056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: 300 mg/m\^2 IV for 1 Day
Study: NCT02549898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BBI-MRI
Description: Black blood MRI scans will be performed in order to asses changes in vessel wall thickness due to possible vascular inflammation associated with migraine attacks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BBI-MRI
Description: Black blood MRI scans will be performed in order to asses changes in vessel wall thickness due to possible vascular inflammation associated with migraine attacks.
Study: NCT02836808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAIPaDi
Description: Patients are attended in 1 day by 9 specialists (endocrinologist, diabetes educators, nutritionist, psychologist, dentists, psychiatrist, physical activity specialist, foot care and ophthalmologist). They are attended in 4 monthly visits. After the initial phase, patients come back to the Center at 1 and 2 years for evaluation and reinforcement.
Study: NCT03886818

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard dressings
Description: Standard dressings will be used from surgery to wound healing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO strategy
Description: The PICO system with negatif pression will be used from surgery to day 7. After that, standard dressing will be used untill the wound Healing.